Please ensure Javascript is enabled for purposes of website accessibility

Pfizer Posts Positive Data from Duchenne Muscular Dystrophy Candidate, but Still Trails Rival Sarepta Therapeutics

By Brian Orelli, PhD - Updated May 15, 2020 at 3:38PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The big pharma is jumping straight to a phase 3 clinical trial for the gene therapy PF-06939926.

Pfizer (PFE 0.56%) released fairly promising data from its trial for the gene therapy PF-06939926 in boys with Duchenne muscular dystrophy. As the long code name implies, the drug is still in an early stage of development, but the data was fairly impressive nonetheless.

In a phase 1b clinical trial, treatment with PF-06939926 resulted in expression of dystrophin, the protein that's missing in patients with Duchenne muscular dystrophy. The three patients given the lower dose had an average of 24% of normal expression of dystrophin in muscle biopsies taken 12 months after treatment with PF-06939926. The three patients treated at the higher dose averaged an even more impressive 51.6% of normal expression of dystrophin.

More importantly, the dystrophin expression appears to be helping the muscles function better. Using the 

The six patients improved their scores on the North Star Ambulatory Assessment (NSAA) -- a measure of muscle function with a top score of 34 -- by an average of 3.5 points. The study didn't have a control group, but based on historical data for untreated Duchenne patients, those patients would have been expected to lose an average of 4 points on the NSAA scale in one year.

Doctor examining a baby's foot

Image source: Getty Images.

Based on the promising data, Pfizer plans to go straight into a phase 3 clinical trial starting in the second half of this year. Beyond the obvious fact that it is aiming to fill an as-yet unmet need for Duchenne patients, Pfizer's decision to skip the phase 2 step may also be due to the competition with Sarepta Therapeutics (SRPT -0.32%).

It's hard to compare results from different clinical trials since they may have enrolled patients at different stages of disease progression, but in its clinical trial, Sarepta Therapeutics' gene therapy SRP-9001 produced a 6-point improvement on the NSAA. The biotech expects data from a placebo-controlled clinical trial of SRP-9001 in the first quarter of next year.

Investors seemed to be willing to look past the issues with cross-clinical-trial comparisons and sent shares of Sarepta Therapeutics up by 11.5% as of 3:30 p.m. EDT on Friday, while shares of much-larger Pfizer were trading down a fraction of a percent.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$49.85 (0.56%) $0.28
Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
$111.11 (-0.32%) $0.36
Solid Biosciences Inc. Stock Quote
Solid Biosciences Inc.
$0.77 (1.94%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.